[{"data":1,"prerenderedAt":161},["ShallowReactive",2],{"content-route-/en/research/rvvc-maintenance-treatment-review-2022":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":21,"projection":143,"alternates":152},"target","/en/research/rvvc-maintenance-treatment-review-2022","en-US",{"kind":8,"family":8,"sectionKeys":9},"research-summary",[10,11,12,13,14,15,16,17,18,19,20],"bottom-line","why-source-matters","study-population","tested","results","applicability","limitations","contribution","practical-change","funding-conflicts","source",{"kind":8,"title":22,"description":23,"firstPublished":24,"evidenceAsOf":24,"lastUpdated":24,"changeNote":25,"research":26,"relations":57,"body":61},"Maintenance treatment for recurrent vulvovaginal candidiasis","A Cochrane review found fewer recurrences during maintenance treatment, with a smaller and uncertain benefit after treatment ended.","2026-07-15","Initial draft summary created from the selected source.",{"sourceId":27,"studyType":28,"population":29,"sampleScale":30,"contribution":31,"contributionRationale":32,"relatedEvidenceMap":33,"funding":34,"conflicts":35,"paperDate":36,"results":37,"applicability":41,"limitations":46,"practicalChange":56},"cochrane-rvvc-treatment-2022","Cochrane systematic review of randomized and quasi-randomized treatment trials","Nonpregnant participants aged 17 to 67 with RVVC confirmed by a positive test; included comparisons covered oral and topical antifungals and several non-drug interventions","23 studies with 2,212 participants; six antifungal-versus-placebo or no-treatment studies included 607 participants at six months","supporting","This broad randomized-evidence review directly traces reduced recurrence during maintenance, weaker durability after treatment, adverse-event reporting gaps, and important population exclusions.","/en/research/evidence/recurrent-vaginal-yeast-symptoms","Nine included studies reported industry funding, three independent funding, and the remainder did not report funding.","The review reports high or unclear risk of bias, including poor blinding and reporting, across mostly small trials.","2022-01-10",[38,39,40],"At six months, clinical recurrence occurred in 64 of 318 participants receiving oral or topical antifungal maintenance and 187 of 289 receiving placebo or no maintenance (20 versus 65 per 100; six studies, 607 participants).","At 12 months, after six months of treatment and six months of observation, the pooled estimate was 625 recurrences per 1,000 with treatment versus 781 per 1,000 with placebo or no treatment (six studies, 585 participants; low-certainty evidence).","Adverse events could not be pooled because studies reported them differently.",{"appliesTo":42,"doesNotApplyTo":44},[43],"Group-level recurrence during and after studied maintenance regimens in nonpregnant people with test-confirmed RVVC",[45],"A reliable permanent cure, individualized drug selection, pregnancy, immunocompromise, or unconfirmed recurrent symptoms",[47,50,53],{"finding":48,"limitation":49},"Maintenance treatment was associated with fewer clinical recurrences at six months.","Certainty was low because of bias, missing data, pharmaceutical funding, and substantial heterogeneity.",{"finding":51,"limitation":52},"A smaller benefit remained at 12 months after maintenance had stopped.","Follow-up evidence was limited and does not support a permanent-eradication claim.",{"finding":54,"limitation":55},"The review included harms as an outcome.","Inconsistent adverse-event reporting prevented a pooled estimate.","No practical change. The review supports maintenance as control during treatment, not a reliable long-term cure or an individualized regimen ranking.",[58],{"group":59,"route":33,"label":60},"evidence","Recurrent vaginal yeast symptoms evidence map",{"type":62,"value":63,"toc":139},"minimark",[64,72,78,84,90,96,102,108,114,120,126],[65,66,68],"content-section",{"section-key":10,"title":67},"Bottom line",[69,70,71],"p",{},"Maintenance antifungal treatment reduced recurrence while treatment continued, but the smaller post-treatment benefit and low-certainty evidence do not support a cure promise.",[65,73,75],{"section-key":11,"title":74},"Why this source matters",[69,76,77],{},"It separates recurrence during maintenance from recurrence after treatment stops and exposes uncertainty in harms and route comparisons.",[65,79,81],{"section-key":12,"title":80},"Study and population",[69,82,83],{},"The review included 23 studies and 2,212 test-confirmed RVVC participants aged 17–67; six placebo or no-treatment comparisons informed the main six-month result.",[65,85,87],{"section-key":13,"title":86},"What was tested",[69,88,89],{},"The review assessed oral and topical maintenance antifungals and other interventions against placebo, no treatment, or another active approach.",[65,91,93],{"section-key":14,"title":92},"Results",[69,94,95],{},"At six months, 64 of 318 treated participants and 187 of 289 comparison participants had a recurrence. At 12 months, pooled risks were 625 versus 781 per 1,000.",[65,97,99],{"section-key":15,"title":98},"Applicability",[69,100,101],{},"The main result concerns nonpregnant people with test-confirmed RVVC. It does not select one regimen or establish durable cure.",[65,103,105],{"section-key":16,"title":104},"Limitations",[69,106,107],{},"Most trials were small; risks of bias, missing data, funding, heterogeneity, and inconsistent adverse-event reporting lowered confidence.",[65,109,111],{"section-key":17,"title":110},"Contribution to the evidence",[69,112,113],{},"Supporting. The review directly supports recurrence control during maintenance and the weaker durability boundary after stopping.",[65,115,117],{"section-key":18,"title":116},"Practical change",[69,118,119],{},"No practical change. Maintenance can control recurrence but should not be described as reliably curative.",[65,121,123],{"section-key":19,"title":122},"Funding and conflicts",[69,124,125],{},"Nine studies reported industry funding, three independent funding, and the remainder did not report funding. The review found high or unclear bias across mostly small trials.",[65,127,129],{"section-key":20,"title":128},"Source",[69,130,131,138],{},[132,133,137],"a",{"href":134,"rel":135},"https://pmc.ncbi.nlm.nih.gov/articles/PMC8744138/",[136],"nofollow","Read the original publication"," (published 10 January 2022).",{"title":140,"searchDepth":141,"depth":141,"links":142},"",2,[],{"sources":144,"claims":150,"safety":151},[145],{"sourceId":27,"title":146,"canonicalId":147,"canonicalUrl":134,"publisher":148,"sourceType":149,"publicationDate":36,"lastChecked":24},"Treatment for recurrent vulvovaginal candidiasis (thrush)","doi:10.1002/14651858.CD009151.pub2","Cochrane","systematic-review",[],[],[153,156,159],{"rel":154,"hreflang":6,"href":155},"alternate","https://candipedia.org/en/research/rvvc-maintenance-treatment-review-2022/",{"rel":154,"hreflang":157,"href":158},"pl-PL","https://candipedia.org/pl/research/leczenie-podtrzymujace-rvvc-przeglad-2022/",{"rel":154,"hreflang":160,"href":155},"x-default",1784685064839]